Clinical Trial Update: REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating everolimus with a calcineurin inhibitor–sparing strategy on renal function after liver transplantation; completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Transplantation

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Liver Transplantation | Phase 3 | Status: COMPLETED | Results posted: 2019-02-28